Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (NASDAQ: CRDF) is a clinical-stage biotechnology company focused on developing novel cancer therapies leveraging PLK1 inhibition, a well-validated oncology drug target. The company's website is www.cardiffoncology.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cardiff Oncology, Inc. does
In the company’s own words
Cardiff Oncology, Inc. (NASDAQ: CRDF) is a clinical-stage biotechnology company focused on developing novel cancer therapies leveraging PLK1 inhibition, a well-validated oncology drug target. The company's website is www.cardiffoncology.com.
Cardiff's lead drug candidate is onvansertib, an oral, small molecule PLK1 inhibitor with a 24-hour half-life designed to be used in combination with standard-of-care cancer therapeutics. Onvansertib is highly potent and selective for PLK1 compared to prior pan-inhibitors, with demonstrated oral bioavailability and a favorable safety profile. In vitro and in vivo studies have shown synergistic effects when onvansertib is combined with various cytotoxic agents including microtubule-targeting agents, topoisomerase inhibitors, antimetabolites, PARP inhibitors, and immunotherapies.
The company is conducting multiple clinical trials across several cancer indications. The primary program, CRDF-004, is a Phase 2 randomized trial evaluating onvansertib in combination with FOLFIRI or FOLFOX and bevacizumab for first-line treatment of RAS-mutated metastatic colorectal cancer. Additional investigator-initiated trials are underway in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia. Recent clinical data from the mTNBC trial presented at ASCO in June 2025 demonstrated a 40 percent objective response rate at the recommended Phase 2 dose.
Cardiff's intellectual property portfolio includes 51 issued patents and 65 pending patent applications covering onvansertib composition of matter, methods of use, and combination therapies. The company licenses onvansertib from Nerviano Medical Sciences under an exclusive worldwide license agreement. Cardiff also maintains an information rights agreement with Pfizer Inc., which purchased equity in the company in 2021 and provides clinical trial services through Pfizer Ignite for the CRDF-004 program.
The company operates one business segment focused on oncology drug development and maintains operations and decision-making functions in the United States, with a laboratory in San Diego, California dedicated to biomarker analysis and drug development optimization.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1213037
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cardiff Oncology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cardiff Oncology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cardiff Oncology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cardiff Oncology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cardiff Oncology, Inc.'s last four quarterly filings that the numbers alone won't show?”